Testosterone deficiency affects 40% of men over the age of 45. 30–50% of men with type 2 diabetes or obesity suffer from testosterone deficiency. The USFDA has recently approved oral testosterone undecanoate (TU) as a testosterone replacement therapy to treat hypogonadism in men . The approved TU is an oral soft gel capsule that can be absorbed through the lymphatic system.
Testosterone undecanoate clinical trial A phase 3 clinical trial conducted on 155 hypogonadal men (18–65 years old) with serum testosterone levels of £281 ng/dL demonstrated the safety and efficacy of the TU. On day 90 of the study, 139 (88%) TU-treated men displayed a normal range of plasma total testosterone concentration (222–800 ng/dL) over 24 hours. The treatment also improved energy/fatigue, positive mood, erectile function, intercourse satisfaction, and quality of life in the patients. Testosterone undecanoate…
